Showing 4581-4590 of 7540 results for "".
- Changes Afoot at Valeant Pharmaceuticalshttps://practicaldermatology.com/news/changes-afoot-at-valeant-pharmaceuticals/2458527/Amid reports that its Obagi Medical Products and Solta Medical units are on the block, Valeant Pharmaceuticals is assuring investors that the company is focused on the future and has plans to fix its dermatology unit. Valeant CEO Joseph Papa cite
- Galderma's Cetaphil® Launches Limited-edition Product Display Honoring Camp Wonderhttps://practicaldermatology.com/news/galdermas-cetaphil-launches-limited-edition-product-display-honoring-camp-wonder/2458529/Galderma Laboratories is unveiling a limited-edition product display in partnership with the Children's Skin Disease Foundation (CSDF) and Camp Wonder, an initiative of the CSDF. As part of a fi
- Preston Romm Joins Suneva Medical As Chief Operating Officerhttps://practicaldermatology.com/news/preston-romm-joins-suneva-medical-as-chief-operating-officer/2458528/Suneva Medical Inc. appointed Preston Romm to chief operating officer (COO). Romm joins Suneva Medical with more than 30 years of experience and will be responsible for leading the company's sales, marketing and operations. Previously serving as president of Oba
- Solta Medical Launches Consumer Campaign to Empower LGBTQ Communityhttps://practicaldermatology.com/news/solta-medical-launches-consumer-campaign-to-empower-lgbtq-community/2458538/Solta Medical, a division of Valeant Pharmaceuticals North America LLC, is supporting the LGBTQ community through a focused consumer campaign that will help shed one more layer to reveal one’s true self. In addition, Solta Medical was the exclusive medical aesthetic category sponsor of the
- Acne Scars: Survey Highlights the Negative Ways Acne and Acne Scars Can Affect Confidencehttps://practicaldermatology.com/news/acne-scars-survey-highlights-the-negative-ways-acne-and-acne-scars-can-affect-quality-of-life/2458539/Ninety-nine percent people would have more confidence if their acne and acne scars were gone, according to a new survey for Suneva Medical. When it comes to skin issues, respondents feel that acne scars are worse than having acne, eczema or rosacea. Nearly half of adults still have
- Dupilumab with Topical Corticosteroids (TCS) Superior to TCS Alone in Long-term Atopic Dermatitis Studyhttps://practicaldermatology.com/news/dupilumab-with-topical-corticosteroids-tcs-superior-to-tcs-alone-in-long-term-atopic-dermatitis-study/2458541/Treatment with investigational dupilumab in combination with topical corticosteroids (TCS) significantly improved measures of overall disease severity, according to one-year results of the LIBERTY AD CHRONOS study. Reported by Regeneron Pharmaceuticals, Inc. and Sanofi, the phase 3 study involved
- No Scrubs? Most Derm Patients Prefer their Docs in White Coatshttps://practicaldermatology.com/news/no-scrubs-most-derm-patients-prefer-their-docs-in-white-coats/2458545/Think you're dressing for success? Think again especially if you are wearing anything other than a traditional white coat when you see patients. The majority of patients prefer their dermatologists to be dressed in white coats, according to a new article pub
- Robert Grant No Longer CEO of Alphaeonhttps://practicaldermatology.com/news/robert-grant-no-longer-ceo-of-alphaeon/2458550/Robert Grant is no longer CEO of Alphaeon, our sister site, Eyewiretoday.com has learned. After 3 years at
- New Nair Survey Shows Unwanted Body Hair is No Confidence Boosterhttps://practicaldermatology.com/news/new-nair-survey-shows-unwanted-body-hair-is-no-confidence-booster/2458552/Just shy of 80 percent of women are more confident when they do not have unwanted body hair, according to a recent online survey conducted by Harris Poll on behalf of Church & Dwight Co., Inc., the makers of Nair™. Who Wears Short Shorts? Nair for Short Shorts</
- FDA Accepts Allergan's NDA Filing for Oxymetazoline HCI Cream 1.0% for Facial Erythemahttps://practicaldermatology.com/news/fda-accepts-allergans-nda-filing-for-oxymetazoline-hci-cream-10/2458553/The FDA accepted Allergan plc's New Drug Application (NDA) filing for oxymetazoline HCl cream 1.0%, an investigational topical prescription product for the treatment of persistent facial erythema (redness) associated with rosacea in adults. Allergan expects the Prescription Drug User Fee